Solid Biosciences Inc [SLDB] stock is trading at $5.77, down -2.53%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SLDB shares have gain 6.26% over the last week, with a monthly amount glided 46.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Solid Biosciences Inc [NASDAQ: SLDB] stock has seen the most recent analyst activity on December 04, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $16. Previously, Citigroup started tracking the stock with Buy rating on June 26, 2025, and set its price target to $14. On January 08, 2025, Truist initiated with a Buy rating and assigned a price target of $16 on the stock. Wedbush started tracking the stock assigning an Outperform rating and suggested a price target of $16 on December 13, 2024. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $15 as its price target on December 10, 2024. JP Morgan upgraded its rating to Overweight for this stock on July 15, 2024, and upped its price target to $15. In a note dated June 24, 2024, Leerink Partners upgraded an Outperform rating on this stock but restated the target price of $12.
Solid Biosciences Inc [SLDB] stock has fluctuated between $2.41 and $7.37 over the past year. Currently, Wall Street analysts expect the stock to reach $13.67 within the next 12 months. Solid Biosciences Inc [NASDAQ: SLDB] shares were valued at $5.77 at the most recent close of the market. An investor can expect a potential return of 136.92% based on the average SLDB price forecast.
Analyzing the SLDB fundamentals
Gross Profit Margin for this corporation currently stands at -0.53% with Operating Profit Margin at -54.32%, Pretax Profit Margin comes in at -53.5%, and Net Profit Margin reading is -53.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is -0.74 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.64 points at the first support level, and at 5.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.03, and for the 2nd resistance point, it is at 6.28.
Ratios To Look Out For
For context, Solid Biosciences Inc’s Current Ratio is 6.74. Also, the Quick Ratio is 6.74, while the Cash Ratio stands at 1.69.
Transactions by insiders
Recent insider trading involved Howton David T, Chief Operating Officer, that happened on Dec 03 ’25 when 4932.0 shares were sold. President and CEO, Cumbo Alexander completed a deal on Dec 03 ’25 to sell 10808.0 shares. Meanwhile, Chief Regulatory Officer Hanrahan Jessie sold 4483.0 shares on Dec 03 ’25.
